Oruka Therapeutics (NASDAQ:ORKA) Bolsa, Quote.MetaTitle.unusual-options

Oruka Therapeutics

Oruka Therapeutics Inc

Ardelyx

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

CureVac

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Immunome

Immatics

Inhibrx Biosciences

MiMedx Group

MannKind

NuCana

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Precigen

Sionna Therapeutics

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

Stoke Therapeutics

Tango Therapeutics

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Upstream Bio

UroGen Pharma

Zymeworks

Oruka Therapeutics (ORKA) Previsión

Noticias

Beneficios

Opciones

Dividendos

Calificaciones de analistas

Operaciones de insiders

Interés en corto

Informe de acciones

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Comments

Oruka Therapeutics Opciones Inusuales

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL